Table 1. Baseline characteristics of participants in EVIDENT study.
| Mean ± SD/Median (IQR)/n (%) | |
| Age (years) | 55.0±13.6 |
| Gender n (%) | |
| Male | 502 (39.10) |
| Female | 782 (60.90) |
| Smoking status n (%) | |
| Never | 613 (47.70) |
| Current | 276 (21.50) |
| Past | 395 (30.80) |
| Alcohol. (g/week) | 10 (70-0) |
| Body mass index (kg/m2) | 26.7 (24.0–29.5) |
| Waist circumference cm | 93 (85.00–100.75) |
| Obesity n (%) | 278 (21.70) |
| Abdominal Obesity n (%) | 560 (43.80) |
| Body fat percentage (%) | 34.80±7.50 |
| Waist/Height cm/cm | 0.56 (0.52–0.61) |
| Body adiposity index | 26.0 (22.2–30.2) |
| Office systolic blood pressure (mmHg) | 124.7±17.0 |
| Office diastolic blood pressure (mmHg) | 77.3±10.6 |
| Mean blood pressure (mmHg) | 92.9±11.5 |
| Hypertension n (%) | 357 (28.00) |
| Fasting glucose (mg/dL) | 89 (82.50–98.00) |
| Glycated hemoglobin (%) | 5.50 (5.30–5.80) |
| HOMA Index | 1.52 (0.86–2.43) |
| Diabetes n (%) | 96 (7.50) |
| Total cholesterol (mg/dL) | 214.29±38.44 |
| Triglycerides (mg/dL) | 96 (71.00–135.00) |
| HDL-cholesterol (mg/dL) | 58.00 (48.75–69.00) |
| LDL-cholesterol (mg/dL) | 133.15±34.65 |
| Dyslipidemia n (%) | 384 (30.10) |
| Lipid lowering drugs n (%) | 238 (18.50) |
| Creatinine. (mg/dL) | 0.8 (0.70–0.90) |
| Haemoglobin (g/dL) | 14.30 (13.50–15.30) |
| Fibrinogen (mg/dL) | 366 (319.00–415.00) |
| Ln Fibrinogen (mg/dL) | 5.90±0.22 |
| hs-CRP (mg/dL) | 0.17 (0.09–0.34) |
| Uric Acid (mg/dL) | 4.80 (3.90–5.90) |
Values are means (standard deviations) for continuous data. Median (interquartile range) for asymmetrically distributed continuous data and number and proportion for categorical data.
Body adiposity index = (hip circumference in centimeters)/(height in meters)1.5 − 18); HDL: High Density Lipoprotein; LDL: low-density lipoprotein; hs-CRP: high-sensitivity C-Reactive Protein.